After assessing its involvement in signaling pathways and measuring the expression of its upstream molecules, we determined that EHMT2 participated in EGFR-TKI resistance by regulating the PTEN/AKT pathway in NSCLC (Fig. 3). This evidence concerns the gene EHMT2 and non-small cell lung carcinoma.